8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

_____________

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of report (Date of earliest event reported): January 9, 2018

STRATA SKIN SCIENCES, INC.

(Exact Name of Registrant Specified in Charter)

Delaware	000-51481	13-3986004
(State or Other	(Commission File	(I.R.S. Employer
Jurisdiction of	Number)	Identification No.)
Incorporation)

100 Lakeside Drive, Suite 100, Horsham, Pennsylvania	19044
(Address of Principal Executive Offices)	(Zip Code)

Registrant's telephone number, including area code:   215-619-3200

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐          Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐          Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐          Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐          Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure

On January 9, 2018, Strata Skin Sciences (the "Company") posted an investor presentation to its website at http://investors.strataskinsciences.com/investors/home.  A copy of the investor presentation is attached as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section, nor shall it be deemed subject to the requirements of amended Item 10 of Regulation S-K, nor shall it be deemed incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing. The furnishing of this information hereby shall not be deemed an admission as to the materiality of any such information.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

99.1 Strata Skin Sciences Investor Presentation dated January 9, 2018.

- 2 -

Exhibit Index

Exhibit No.	Exhibit Description
99.1	January 9, 2018 STRATA Skin Sciences, Inc. investor presentation

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	STRATA SKIN SCIENCES, INC.
Date: January 9, 2018	By:	/s/ Frank J. McCaney
		Frank J. McCaney
		President & Chief Executive Officer

- 3 -

EX-99.1

EXHIBIT 99.1

 “With their patented Selective Waveband Technology, the system will address what normally I need 5 systems to treat”  - Grant Stevens, MD, F.A.C.S.Plastic Surgeon  CONFIDENTIAL - DO NOT DISTRIBUTE 

 “With their patented Selective Waveband Technology, the system will address what normally I need 5 systems to treat”  - Grant Stevens, MD, F.A.C.S.Plastic Surgeon  STRATA ACTIVITIES  STRATA SKIN SCIENCESWe Believe in Better  Dedicated to Skin SciencesMedical Dermatology XTRAC Laser and Systems for Psoriasis, Eczema, VitiligoAesthetics Nordlys Multiplatform Laser Stratapen for Microneedling  Large Opportunities, Better Products, Mix of Reimbursed and For Pay Offerings 

 “With their patented Selective Waveband Technology, the system will address what normally I need 5 systems to treat”  - Grant Stevens, MD, F.A.C.S.Plastic Surgeon  STRATA ACTIVITIES  STRATA SKIN SCIENCESWe Believe in Better  2016 ResultsRevenues $31.7MGM 60.2%GAAP Adj. EBITDA $2.9MNo Guidance for 20172017 ChangesDiscontinuation of MelaFind productDistribution Agreement for Nordlys Aesthetic LaserOEM Relationship for StratapenConversion of Debt to StockRealignment of Significant Field Infrastructure, Refinement of Business Model 

 “With their patented Selective Waveband Technology, the system will address what normally I need 5 systems to treat”  - Grant Stevens, MD, F.A.C.S.Plastic Surgeon  STRATA ACTIVITIES  STRATA SKIN SCIENCESWe Believe in Better  Recent EventsWhen created in mid-2015, Strata acquired the XTRAC business for $43M in debtConversion of $41M in Debt to Preferred Stock with easy conversion to CommonStrata eliminates $1M interest for next four yearsWill utilize savings and balance sheet to foster acquisitions and internal project development 

 “With their patented Selective Waveband Technology, the system will address what normally I need 5 systems to treat”  - Grant Stevens, MD, F.A.C.S.Plastic Surgeon  STRATA ACTIVITIES  Medical DermatologyWe Believe in Better  XTRAC Excimer Laser, VTRAC lamp systemPsoriasis 6-8M patients USOver 2M treatments performedFully reimbursed treatmentProven EffectiveOutstanding Side Effect ProfileWorking on next gen recurring revenue product (2018) with the goal of significantly expanding our addressable market 

 “With their patented Selective Waveband Technology, the system will address what normally I need 5 systems to treat”  - Grant Stevens, MD, F.A.C.S.Plastic Surgeon  STRATA ACTIVITIES  STRATA SKIN SCIENCESWe Believe in Better  Psoriasis  Vitiligo 

           Over the Counter Topicals  Rx Topicals  XTRAC Targeted Phototherapy  Biologics  InexpensiveLow efficacyFew side effects  More expensiveModerate efficacyLow/Moderateside effects  Cost effectiveExcellent efficacywith finite numberof treatmentsVirtually noside effects  Very expensiveVery good efficacySignificantside effects  XTRAC: Ideally Positioned 

 “With their patented Selective Waveband Technology, the system will address what normally I need 5 systems to treat”  - Grant Stevens, MD, F.A.C.S.Plastic Surgeon  STRATA ACTIVITIES  Medical AestheticsWe Believe in Better  NordlysDistribution Agreement for US with Ellipse A/SAesthetic Platform with SWT (next gen IPL), YAG Laser and FRAXBetter product for enhanced Patient comfort6,500 placements WW but only 400 USSignificant growth in Aesthetics with both core and non-core physicians. Nordlys is less painful and cuts downtime post procedure for most applications 

   9  Treats Skin Types I-VI3 Year WarrantyFastest Patient ThroughputPatented Dual-Mode FiltrationLow Fluence RequiredFewer Pulses Per Treatment  “It’s been getting patients into the office for hair reduction, pigments, rosacea…virtually painless..less treatments…great results”-John M. Taylor, MDPlastic Surgeon   

 “With their patented Selective Waveband Technology, the system will address what normally I need 5 systems to treat”  - Grant Stevens, MD, F.A.C.S.Plastic Surgeon 

 Photo Rejuvenation          Photo Rejuvenation      Pigmentation3 Treatments • 90 Days    Pigmentation1 Treatment • 120 Days  Pulses/Tx  J/cm2  70  8  Single Treatment  Total Pulses  Total J/cm2  210  1680  Treatment Total  Pulses/Tx  J/cm2  10  10  Single Treatment  Total Pulses  Total J/cm2  10  100  Treatment Total  PIGMENT CONCERNS 

 “With their patented Selective Waveband Technology, the system will address what normally I need 5 systems to treat”  - Grant Stevens, MD, F.A.C.S.Plastic Surgeon    StratapenApproved for delivery of pigment under the skinPatented features to prevent contaminationBetter pull through the skinRegionally sold until our OEM AgreementGetting strong reviews from KOLsStrong Disposable Trail 

 “With their patented Selective Waveband Technology, the system will address what normally I need 5 systems to treat”  - Grant Stevens, MD, F.A.C.S.Plastic Surgeon  STRATA ACTIVITIES  STRATA 2018We Believe in Better  Improve Profitability of XTRAC Business, Adapt to Changing EnvironmentRevitalize B2B and B2C Activities, launching comprehensive digital platform in Q1Leverage Sales and Support Infrastructure (60 people), Get Traction with distributed/ OEM products, gain additional accessPartner with Customers by providing best-in-class products for Practice Revenue with bothReimbursed Medical Procedures, andAesthetic For Pay Procedures 

 “With their patented Selective Waveband Technology, the system will address what normally I need 5 systems to treat”  - Grant Stevens, MD, F.A.C.S.Plastic Surgeon  STRATA ACTIVITIES  STRATA 2018 and 2019We Believe in Better  Renew the XTRAC business with shorter protocols and enhanced H/W and UI/UXMake the treatments more convenient and more efficaciousGraphical interface for patient dataDevelop versions that will be amenable to penetrating socialized medicine marketsNew Products in the Aesthetic spaceAlready under developmentOther Business Development, capacity in Sales 

 “With their patented Selective Waveband Technology, the system will address what normally I need 5 systems to treat”  - Grant Stevens, MD, F.A.C.S.Plastic Surgeon  STRATA ACTIVITIES  STRATA SKIN SCIENCESWe Believe in Better  Sales and support now up to speed on the two advantaged Aesthetic products, can drive incremental revenues at higher net profit levelsRevamping our tools for patient awareness and driving repeat business through Social MediaUpdating and Upgrading the XTRAC franchise to capture significantly more market shareHaving Value Solutions and Educational Support to help Medical Practices grow revenues and attract patients  Summary 

 “With their patented Selective Waveband Technology, the system will address what normally I need 5 systems to treat”  - Grant Stevens, MD, F.A.C.S.Plastic Surgeon